Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products: Fludarabine Phosphate for Injection, USP and Epirubicin Hydrochloride Injection

-- First oncology products introduced from Sagent's extensive pipeline --

SCHAUMBURG, Ill., Aug. 5 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched fludarabine phosphate for injection, USP and epirubicin hydrochloride injection. IMS data indicates the combined U.S. market for these two products approximated $25 million in 2008. Sagent will begin marketing and shipping both products immediately.

"We are very pleased to begin expanding our product line to include vital oncology products," said Jeffrey M. Yordon, chief executive officer, founder and chairman of the board of Sagent. "Our epirubicin and fludarabine products are each latex and preservative free, and bear Sagent's hallmark packaging, designed to help healthcare providers quickly and accurately identify the right product and dose."

Fludarabine for injection, USP will be offered in 50 mg single-use vials. Epirubicin hydrochloride injection will be offered in 50 mg per 25 mL and 200 mg per 100 mL single-dose vials.

About Fludarabine Phosphate for Injection, USP

Fludarabine phosphate for injection, USP (generic equivalent to Fludara(R), distributed by Bayer HealthCare Pharmaceuticals) is indicated for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. The safety and effectiveness of the product in previously untreated or non-refractory patients with CLL have not been established.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile, boxed warnings and prescribing information.

About Epirubicin Hydrochloride Injection

Epirubicin hydrochloride injection (generic equivalent to Ellence(R), distributed by Pfizer Oncology) is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile, boxed warnings and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.

SOURCE Sagent Pharmaceuticals, Inc.